Pharmaceuticals company OneSource Specialty Pharma announced Q2FY26 results Revenues at Rs 3,758 million, up 12% YoY. EBITDA grew 37% YoY to Rs 1,065 million. EBITDA margin of 28%, an expansion of ~506 bps YoY. Adjusted PAT stood at Rs 449 million with adjusted EPS of Rs 3.9. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: “Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to USD 500 million+.” Result PDF